Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
Patrick G. Pilié(The University of Texas MD Anderson Cancer Center), Timothy A. Yap(Royal Marsden Hospital)
Cited by 11
Related Papers
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
|CA A Cancer Journal for Clinicians|2011|209
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
|Clinical Cancer Research|2021|134
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
|Nature Medicine|2023|100
Protein Microarray Analysis of Mammary Epithelial Cells from Obese and Nonobese Women at High Risk for Breast Cancer: Feasibility Data
|Cancer Epidemiology Biomarkers & Prevention|2011|15